NCT05960370

Brief Summary

Multicenter prospective observational cohort study, comparing ongoing pregnancy rates in natural cycles for euploid embryo transfer in patients who present endometrial compaction at the time of the transfer versus those who have a stable or greater endometrial thickness with respect to the estrogenic phase.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
206

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 15, 2022

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

July 17, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 25, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2025

Completed
Last Updated

October 3, 2024

Status Verified

October 1, 2024

Enrollment Period

3 years

First QC Date

July 17, 2023

Last Update Submit

October 2, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Ongoing pregnancy rate

    Presence of an intrauterine pregnancy with positive embryo heartbeat as seen by sonography at 8-10 weeks gestational age.

    8-10 weeks gestational age.

Secondary Outcomes (4)

  • Biochemical pregnancy loss

    9-10 days after the embryo transfer.

  • Clinical pregnancy

    5-6 weeks gestational age.

  • Ectopic pregnancy

    5-8 weeks gestational age.

  • Early pregnancy loss

    5-10 weeks gestational age.

Study Arms (2)

exposed or "compaction" group

103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).

Other: Observational non intervention study

non-exposed "non-compaction" group

103 women with similar or greater endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).

Other: Observational non intervention study

Interventions

An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.

exposed or "compaction" groupnon-exposed "non-compaction" group

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen undergoing fertility treatment.
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

206 Women between 18-50 years, with primary or secondary infertility, undergoing fertility treatment that includes endometrial preparation in a modified natural cycle for transfer of previously analyzed frozen and euploid embryos.

You may qualify if:

  • Aged 18 to 50 years
  • Primary or secondary infertility
  • Normal uterine cavity
  • Endometrial preparation in a modified natural cycle for single embryo transfer
  • Embryo in blastocyst state from own oocyte or oocyte donation cycles, who had normal results on preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy.

You may not qualify if:

  • Uterine or endometrial disease (multiple myomatosis \[\>3 fibroids of \> 3 cm\], adenomyosis, Asherman syndrome)
  • Difficulties in correctly measuring endometrial thickness due to a retroverted or tilted uterus
  • History of recurrent implantation failure (3 or more transferred blastocysts of good quality, from their own oocyte \[\<35 years\] or oocyte donation); recurrent early Pregnancy Loss (the loss of two or more pregnancies before 10 weeks of gestational age.
  • Suboptimal endometrial response (endometrium \< 6 mm on the day of ovulation triggering).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Bernabeu

Madrid, 28001, Spain

RECRUITING

Study Officials

  • Juan Carlos J Castillo Farfan, Doctor

    Instituto Bernabeu Alicante

    STUDY DIRECTOR

Central Study Contacts

Esperanza E de la Torre Pérez, Gynecologist

CONTACT

Juan Carlos J Castillo Farfan, Doctor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
4 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Gynecologist

Study Record Dates

First Submitted

July 17, 2023

First Posted

July 25, 2023

Study Start

June 15, 2022

Primary Completion

June 15, 2025

Study Completion

June 15, 2025

Last Updated

October 3, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations